businesspress24.com - Threshold Pharmaceuticals Announces Presentation and Webcast at 11th Annual BIO Investor Forum
 

Threshold Pharmaceuticals Announces Presentation and Webcast at 11th Annual BIO Investor Forum

ID: 1157260

(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/04/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 11th Annual BIO Investor Forum at 2:30 p.m. PT on October 10, 2012, taking place in San Francisco, CA.

A recording of the presentation will be available one hour after conclusion of the live event under Webcasts in the Investors section of , and will be archived there for 30 days.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ().

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on August 6, 2012 and is available from the SEC's website () and on our website () under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.







Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
E-mail:


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Boston Therapeutics Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET(TM) to Treat Diabetes
Sialix Executes Option Agreement; Appoints New Management Team to Advance Sialic Acid-Based Products for Treatment and Prevention of Cancer and Inflammation
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 04.10.2012 - 05:30 Uhr
Sprache: Deutsch
News-ID 1157260
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SOUTH SAN FRANCISCO, CA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 223 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Threshold Pharmaceuticals Announces Presentation and Webcast at 11th Annual BIO Investor Forum
"
steht unter der journalistisch-redaktionellen Verantwortung von

Threshold Pharmaceuticals (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Threshold Pharmaceuticals



 

Who is online

All members: 10 567
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 82


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.